These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 26458959)

  • 1. Focal irreversible electroporation for prostate cancer: functional outcomes and short-term oncological control.
    Ting F; Tran M; Böhm M; Siriwardana A; Van Leeuwen PJ; Haynes AM; Delprado W; Shnier R; Stricker PD
    Prostate Cancer Prostatic Dis; 2016 Mar; 19(1):46-52. PubMed ID: 26458959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feasibility and safety of focal irreversible electroporation as salvage treatment for localized radio-recurrent prostate cancer.
    Scheltema MJ; van den Bos W; Siriwardana AR; Kalsbeek AMF; Thompson JE; Ting F; Böhm M; Haynes AM; Shnier R; Delprado W; Stricker PD
    BJU Int; 2017 Nov; 120 Suppl 3():51-58. PubMed ID: 28834167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Focal irreversible electroporation as primary treatment for localized prostate cancer.
    van den Bos W; Scheltema MJ; Siriwardana AR; Kalsbeek AMF; Thompson JE; Ting F; Böhm M; Haynes AM; Shnier R; Delprado W; Stricker PD
    BJU Int; 2018 May; 121(5):716-724. PubMed ID: 28796935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preliminary Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging to Detect Residual Prostate Cancer Following Focal Therapy with Irreversible Electroporation.
    Scheltema MJ; Chang JI; van den Bos W; Böhm M; Delprado W; Gielchinsky I; de Reijke TM; de la Rosette JJ; Siriwardana AR; Shnier R; Stricker PD
    Eur Urol Focus; 2019 Jul; 5(4):585-591. PubMed ID: 29102671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate cancer treatment with Irreversible Electroporation (IRE): Safety, efficacy and clinical experience in 471 treatments.
    Guenther E; Klein N; Zapf S; Weil S; Schlosser C; Rubinsky B; Stehling MK
    PLoS One; 2019; 14(4):e0215093. PubMed ID: 30986263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Focal vs extended ablation in localized prostate cancer with irreversible electroporation; a multi-center randomized controlled trial.
    Scheltema MJ; van den Bos W; de Bruin DM; Wijkstra H; Laguna MP; de Reijke TM; de la Rosette JJ
    BMC Cancer; 2016 May; 16():299. PubMed ID: 27150293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncological and Quality-of-life Outcomes Following Focal Irreversible Electroporation as Primary Treatment for Localised Prostate Cancer: A Biopsy-monitored Prospective Cohort.
    Blazevski A; Scheltema MJ; Yuen B; Masand N; Nguyen TV; Delprado W; Shnier R; Haynes AM; Cusick T; Thompson J; Stricker P
    Eur Urol Oncol; 2020 Jun; 3(3):283-290. PubMed ID: 31103721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Focal ablation of apical prostate cancer lesions with irreversible electroporation (IRE).
    Blazevski A; Amin A; Scheltema MJ; Balakrishnan A; Haynes AM; Barreto D; Cusick T; Thompson J; Stricker PD
    World J Urol; 2021 Apr; 39(4):1107-1114. PubMed ID: 32488359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pair-matched patient-reported quality of life and early oncological control following focal irreversible electroporation versus robot-assisted radical prostatectomy.
    Scheltema MJ; Chang JI; Böhm M; van den Bos W; Blazevski A; Gielchinsky I; Kalsbeek AMF; van Leeuwen PJ; Nguyen TV; de Reijke TM; Siriwardana AR; Thompson JE; de la Rosette JJ; Stricker PD
    World J Urol; 2018 Sep; 36(9):1383-1389. PubMed ID: 29594551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial assessment of safety and clinical feasibility of irreversible electroporation in the focal treatment of prostate cancer.
    Valerio M; Stricker PD; Ahmed HU; Dickinson L; Ponsky L; Shnier R; Allen C; Emberton M
    Prostate Cancer Prostatic Dis; 2014 Dec; 17(4):343-7. PubMed ID: 25179590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salvage robot-assisted radical prostatectomy following focal ablation with irreversible electroporation: feasibility, oncological and functional outcomes.
    Blazevski A; Gondoputro W; Scheltema MJ; Amin A; Geboers B; Barreto D; Haynes AM; Shnier R; Delprado W; Agrawal S; Thompson JE; Stricker PD
    BMC Urol; 2022 Mar; 22(1):28. PubMed ID: 35236338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-reported functional outcomes and oncological control after primary focal cryotherapy for clinically significant prostate cancer: A Phase II mandatory biopsy-monitored study.
    Tan YG; Law YM; Ngo NT; Khor LY; Tan PH; Ong EHW; Yuen JSP; Ho HSS; Tuan JKL; Kanesvaran R; Gupta RT; Rozen S; Chua MLK; Polascik TJ; Tay KJ
    Prostate; 2023 Jun; 83(8):781-791. PubMed ID: 36895163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Focal cryoablation: a treatment option for unilateral low-risk prostate cancer.
    Durand M; Barret E; Galiano M; Rozet F; Sanchez-Salas R; Ahallal Y; Macek P; Gaya JM; Cerruti J; Devilliers H; Loeffler J; Amiel J; Vallancien G; Cathelineau X
    BJU Int; 2014 Jan; 113(1):56-64. PubMed ID: 24053685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of salvage radical prostatectomy after initial irreversible electroporation treatment for recurrent prostate cancer.
    van Riel LAMJG; Geboers B; Kabaktepe E; Blazevski A; Reesink DJ; Stijns P; Stricker PD; Casanova J; Dominguez-Escrig JL; de Reijke TM; Scheltema MJ; Oddens JR
    BJU Int; 2022 Nov; 130(5):611-618. PubMed ID: 35474600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate cancer treated with irreversible electroporation: MRI-based volumetric analysis and oncological outcome.
    Giganti F; Stabile A; Giona S; Marenco J; Orczyk C; Moore CM; Allen C; Kirkham A; Emberton M; Punwani S
    Magn Reson Imaging; 2019 May; 58():143-147. PubMed ID: 30768957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Image-guided Irreversible Electroporation of Localized Prostate Cancer: Functional and Oncologic Outcomes.
    Collettini F; Enders J; Stephan C; Fischer T; Baur ADJ; Penzkofer T; Busch J; Hamm B; Gebauer B
    Radiology; 2019 Jul; 292(1):250-257. PubMed ID: 31161973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two-year Outcomes Following Focal Laser Ablation of Localized Prostate Cancer.
    Chao B; Llukani E; Lepor H
    Eur Urol Oncol; 2018 Jun; 1(2):129-133. PubMed ID: 31100236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surveillance after prostate focal therapy.
    Tay KJ; Amin MB; Ghai S; Jimenez RE; Kench JG; Klotz L; Montironi R; Muto S; Rastinehad AR; Turkbey B; Villers A; Polascik TJ
    World J Urol; 2019 Mar; 37(3):397-407. PubMed ID: 29948045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Focal therapy for prostate cancer with irreversible electroporation: Oncological and functional results of a single institution study.
    Yaxley WJ; Gianduzzo T; Kua B; Oxford R; Yaxley JW
    Investig Clin Urol; 2022 May; 63(3):285-293. PubMed ID: 35534217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Focal Therapy for Prostate Cancer with In-Bore MR-guided Focused Ultrasound: Two-Year Follow-up of a Phase I Trial-Complications and Functional Outcomes.
    Tay KJ; Cheng CWS; Lau WKO; Khoo J; Thng CH; Kwek JW
    Radiology; 2017 Nov; 285(2):620-628. PubMed ID: 28654336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.